8-K: Elicio Therapeutics Announces Encouraging Preliminary Survival Data for Cancer Vaccine ELI-002 7P

Elicio Therapeutics reported that patients receiving the Phase 2 dose of their cancer vaccine ELI-002 7P have not reached median disease-free survival in an ongoing Phase 1a study.

Summary

• Elicio Therapeutics announced preliminary disease-free survival (DFS) data from its AMPLIFY-7P Phase 1a study of ELI-002 7P, a cancer vaccine targeting mKRAS-driven solid tumors.
• The study included 14 patients, with data cut off on May 24, 2024, and a median follow-up of 29.1 weeks for the DFS endpoint.
• Patients receiving the 4.9 mg AMP-peptide dose (n=8) have not reached median DFS, while those receiving the 1.4 mg dose (n=6) had a median DFS of 12.6 weeks.
• Patients who showed a reduction in tumor biomarker levels had no progression events, compared to a median DFS of 11.0 weeks for those whose biomarkers did not respond.
• Patients with an above-median T cell response to ELI-002 7P have had no progression events as of the data cutoff date.

Sentiment

Score: 7

Explanation: The document presents positive preliminary data, particularly the lack of median DFS being reached in the higher dose group, but it is still early-stage data with a small sample size. The company is also comparing its results to previous trials and industry standards, which is a positive sign.

Positives

• The 4.9 mg dose of ELI-002 7P shows promising results with median DFS not yet reached.
• A strong T cell response correlates with reductions in tumor biomarker levels and reduced risk of progression.
• The findings replicate results from the AMPLIFY-2P trial published in Nature Medicine.
• The 7-peptide formulation of ELI-002 is designed to target seven common KRAS mutations, potentially increasing the patient population.

Negatives

• Patients receiving the lower 1.4 mg dose had a median DFS of only 12.6 weeks.
• Patients whose tumor biomarkers did not respond to ELI-002 7P had a median DFS of 11.0 weeks.

Risks

• The data is preliminary and based on a small sample size of 14 patients.
• The median follow-up of 29.1 weeks may not be sufficient to fully assess long-term survival benefits.
• The study is ongoing, and further data is needed to confirm these findings.

Future Outlook

Elicio anticipates providing additional clinical data updates from the AMPLIFY Phase 1 trials later in 2024 and the randomized Phase 2 interim analysis in the first quarter of 2025.

Management Comments

• Christopher Haqq, M.D., Ph.D., stated that they are encouraged to see patients who received the 7-peptide version of ELI-002 at the Phase 2 dose continuing to do well at this early timepoint of the Phase 1 trial.
• Management noted that the DFS data correlates with strong T cell response and reductions in tumor biomarker levels.

Industry Context

This announcement is part of the broader trend in the biotechnology industry focusing on developing targeted immunotherapies for cancer, particularly those driven by specific mutations like mKRAS. The use of lymph node-targeted delivery systems is also a growing area of interest.

Comparison to Industry Standards

• The results of the ELI-002 7P trial are being compared to the AMPLIFY-2P trial, which was published in Nature Medicine, suggesting a benchmark for the company's own research.
• The company is also comparing its approach to other mKRAS targeting methods, such as small molecule inhibitors, highlighting the potential advantages of their lymph node-targeted vaccine approach.
• The company is aiming to improve on previous cancer vaccine efforts that have not generated a sufficient T cell response, by targeting the lymph nodes.

Stakeholder Impact

• Shareholders may react positively to the encouraging preliminary survival data.
• Patients with mKRAS-driven solid tumors may benefit from the development of this new treatment option.
• Employees may be motivated by the progress of the clinical trials.

Next Steps

• The company plans to provide additional clinical data updates from the AMPLIFY Phase 1 trials later in 2024.
• A randomized Phase 2 interim analysis is expected in the first quarter of 2025.
• The company plans to complete enrollment for the Phase 2 trial of ELI-002 7P in Q4 2024.
• The company plans to initiate an ELI-002 Phase 1B Colorectal Cancer study.
• The company plans to advance ELI-007 and ELI-008 into Phase 1 trials.

Key Dates

Keywords

ELI-002 7P, mKRAS, cancer vaccine, immunotherapy, disease-free survival, T cell response, tumor biomarker, lymph node, AMP technology, pancreatic cancer